In the relentless battle against tuberculosis, a disease that claims over a million lives annually, researchers at the University of Guelph have made a groundbreaking discovery. They've identified a potential drug target within the bacterium's stress-response system, offering a glimmer of hope in the fight against this deadly infection. This finding is particularly significant given the growing resistance to current antibiotics, which primarily target DNA replication and protein synthesis.
The focus of this research is the proteasome, the bacterial equivalent of a recycling center. Here, damaged proteins are broken down after being selected for destruction. The key player in this process is the Bacterial proteasome activator (Bpa), a protein complex that acts as the sorting gate. Bpa's role is crucial in clearing damaged proteins, which is essential for the bacterium's survival under the constant attack of the immune system.
What makes Bpa so intriguing is its ability to recognize target proteins by identifying exposed "greasy" patches, which are normally hidden inside healthy proteins but become visible when proteins are damaged or stressed. However, the exact mechanism by which Bpa decides which proteins to grab has been a mystery, partly due to the instability of its natural targets, making them difficult for researchers to study.
To overcome this challenge, Bradley Davis, a PhD candidate and lead author of the study, engineered a model Bpa substrate using a piece of human protein. This creative approach allowed the research team to map, at a near-atomic level, how Bpa recognizes target proteins and reorganizes into its active form in response to stress. The findings suggest that under warmer, more stressful conditions, such as inside immune cells, the Bpa complex assembles from smaller inactive units into a ring-shaped structure, enhancing its ability to grab proteins and send them to the proteasome for breakdown.
This ability of Bpa to shape-shift in response to stress may be crucial for the bacterium's survival in the human body. Once researchers understand what Bpa is looking for, they can start thinking about ways to fool or block it, providing a new avenue for drug designers. The implications are profound: a new type of antibiotic that doesn't kill the bacterium outright but instead disables its stress-response machinery, leaving it vulnerable to the immune system.
This research is a collaborative effort between the Vahidi lab, Dr. Lewis Kay's lab at the University of Toronto, and scientists at Waters Corporation, who provided access to state-of-the-art mass spectrometry instrumentation. The work opens the door to a different kind of antibiotic, one that may not kill the bacterium outright but instead disables its stress-response machinery, offering a new strategy in the fight against tuberculosis. While this is the long game, it represents a significant step forward in the battle against a disease that has plagued humanity for centuries.
